DWJ 1366

Drug Profile

DWJ 1366

Alternative Names: DWC20155/DWC20156; DWC20156/DWC20155; DWJ1366

Latest Information Update: 28 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Daewoong Pharmaceutical
  • Class Antiulcers
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Gastrointestinal ulcer

Most Recent Events

  • 14 Jun 2017 Daewoong Pharmaceutical plans a phase III trial for Gastritis (Combination therapy, Monotherapy) (NCT03184415)
  • 04 Jan 2017 Daewoong Pharmaceutical initiates enrolment in a phase I drug-drug interaction trial in Healthy volunteers in South Korea (PO) (NCT03005223)
  • 01 Jan 2017 Daewoong Pharmaceutical completes a phase I trial in Healthy volunteers in South Korea (NCT02952547)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top